Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Lymphoma
  Free Subscription

Articles published in
Br J Dermatol
    April 2024
  1. BLANCHARD M, Morren MA, Busschots AM, Hauben E, et al
    Paediatric onset lymphomatoid papulosis: results of a multicentre retrospective cohort study, on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG).
    Br J Dermatol. 2024 Apr 10:ljae150. doi: 10.1093.
    >> Share

  2. ROCCUZZO G, Calvao J, Dobos G, Morsia E, et al
    Cutaneous T-cell lymphoma care across Europe: insights from the Horizon Project.
    Br J Dermatol. 2024 Apr 5:ljae145. doi: 10.1093.
    >> Share

    February 2024
  3. STAMMLER R, Ta VA, Cohen E, Ram-Wolff C, et al
    Failure of second challenge with Mogamulizumab in CCR4-positive cutaneous T-cell lymphoma.
    Br J Dermatol. 2024 Feb 23:ljae085. doi: 10.1093.
    >> Share

  4. JUNG JM, Cho HS, Kim GH, Won CH, et al
    Psoriasiform mycosis fungoides: a clinical and prognostic retrospective cohort study.
    Br J Dermatol. 2024;190:432-434.
    >> Share

    January 2024
  5. TRUM NA, Chen L, Zain J, Rosen ST, et al
    Significant survival disparity in Black patients with cutaneous lymphoma: a retrospective cohort study.
    Br J Dermatol. 2024 Jan 29:ljae039. doi: 10.1093.
    >> Share

    October 2023

  6. Multiple skin lesions, especially on the legs, predict a poorer prognosis in skin lymphoma with large tumour cells.
    Br J Dermatol. 2023;189:e98.
    >> Share


  7. The effect of extracorporeal photopheresis on cytokines released by leukaemic cutaneous T-cell lymphoma.
    Br J Dermatol. 2023;189:e97.
    >> Share

    September 2023
  8. WEINER D, Ly A, Talluru S, Munjal A, et al
    Efficacy of single-agent chemotherapy with pegylated liposomal doxorubicin or gemcitabine in a diverse cohort of patients with recalcitrant cutaneous T-cell lymphoma.
    Br J Dermatol. 2023 Sep 1:ljad311. doi: 10.1093.
    >> Share

    August 2023
  9. MIYAGAKI T, Inoue N, Kamijo H, Boki H, et al
    Prognostic factors for primary cutaneous anaplastic large cell lymphoma: a multicenter retrospective study from Japan.
    Br J Dermatol. 2023 Aug 4:ljad266. doi: 10.1093.
    >> Share

    July 2023
  10. PILERI A, Pimpinelli N
    The role of the immune system in cutaneous T-cell lymphoma, an area requiring more investigation.
    Br J Dermatol. 2023 Jul 24:ljad255. doi: 10.1093.
    >> Share


  11. An oncogene-targeted therapy for Merkel cell carcinoma.
    Br J Dermatol. 2023;189:e33.
    >> Share

  12. WAN J, Shin DB, Syed MN, Abuabara K, et al
    Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2023;189:53-61.
    >> Share

  13. TSAI YC, Schlaepfer T, Ignatova D, Chang YT, et al
    Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in leukaemic cutaneous T-cell lymphoma patients.
    Br J Dermatol. 2023 Jul 6:ljad220. doi: 10.1093.
    >> Share

    May 2023
  14. ALONSO-ALONSO R, Rodriguez M, Garcia-Diaz N, Tomas-Roca L, et al
    NanoString analysis of mycosis fungoides reveals individual molecular identity.
    Br J Dermatol. 2023;188:812-814.
    >> Share

  15. PETERKNECHT E, Scarisbrick J
    Skin Swabs in the Skin Lymphoma Clinic - From Swab to Treatment.
    Br J Dermatol. 2023 May 13:ljad160. doi: 10.1093.
    >> Share

    March 2023
  16. FAN K, Srinivas N, Kubat L, Gravemeyer J, et al
    B-cell lymphoma extra-large (Bcl-xL) is a promising drug target in Merkel cell carcinoma.
    Br J Dermatol. 2023 Mar 30:ljad099. doi: 10.1093.
    >> Share

    February 2023
  17. BROWN-KORSAH JB, Omar D, Wang X, Taylor SC, et al
    Factors contributing to time to chemotherapy, immunotherapy and radiation for patients with mycosis fungoides in the United States National Cancer Database.
    Br J Dermatol. 2023;188:299-301.
    >> Share

    January 2023
  18. OYMANNS M, Daum-Marzian M, Bellm A, Elsayad K, et al
    Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma.
    Br J Dermatol. 2023;188:145-146.
    >> Share

    November 2022
  19. BONTOUX C, de Masson A, Thonnart N, Ram-Wolff C, et al
    Large-cell transformation is an independent poor prognostic factor in Sezary syndrome: analysis of 117 cases.
    Br J Dermatol. 2022;187:815-817.
    >> Share

    August 2022
  20. KEMPF W
    Follicular T helper cells and cutaneous T-cell lymphomas.
    Br J Dermatol. 2022 Aug 31. doi: 10.1111/bjd.21839.
    >> Share


  21. Better understanding about the severity of disease in cutaneous T-cell lymphoma from studying immune checkpoint receptors.
    Br J Dermatol. 2022;187:e69-e76.
    >> Share

  22. DI RAIMONDO C, Rubio-Gonzalez B, Palmer J, Weisenburger DD, et al
    Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sezary syndrome: association with disease stage and clinical outcome.
    Br J Dermatol. 2022;187:234-243.
    >> Share

  23. JIANG TT, Kruglov O, Geskin L, Akilov OE, et al
    Repetitive expanded T-cell receptor clonotypes impart the classic T helper 2 Sezary cell phenotype.
    Br J Dermatol. 2022;187:265-267.
    >> Share

  24. BUECHLER CR, Sagher E, Tisack A, Jacobsen G, et al
    Demographic factors and disparate outcomes in mycosis fungoides: retrospective analysis of a racially diverse 440-patient cohort from Detroit, Michigan, USA.
    Br J Dermatol. 2022;187:246-248.
    >> Share

    July 2022
  25. WANG L, Rocas D, Dalle S, Sako N, et al
    Primary cutaneous peripheral T-cell lymphomas with a T follicular helper phenotype: An integrative clinical, pathological, and molecular case series study.
    Br J Dermatol. 2022 Jul 27. doi: 10.1111/bjd.21791.
    >> Share

  26. ROCCUZZO G, Fava P, Avallone G, Aquino C, et al
    Time to next treatment and safety assessment in Cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21772.
    >> Share

  27. WANG J, Ram-Wolff C, Dobos G, Al Hage J, et al
    Head and neck granulomatous rash associated with mogamulizumab mimicking mycosis fungoides.
    Br J Dermatol. 2022;187:129-131.
    >> Share

    June 2022
  28. BATTESTI G, Ram-Wolff C, Dobos G, Aubin F, et al
    Granulomatous slack skin: clinical characteristics, prognosis, and response to therapy. A study from the Cutaneous Lymphoma French Study Group.
    Br J Dermatol. 2022 Jun 6. doi: 10.1111/bjd.21699.
    >> Share

  29. ROELENS M, de Masson A, Andrillon A, Ram-Wolff C, et al
    Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sezary syndrome.
    Br J Dermatol. 2022;186:1010-1025.
    >> Share

    May 2022
  30. MARTIN-MORO F, Martin-Rubio I, Garcia-Vela JA
    TRBC1 expression assessed by flow cytometry as a novel marker of clonality in cutaneous alphabeta T-cell lymphomas with peripheral blood involvement.
    Br J Dermatol. 2022 May 23. doi: 10.1111/bjd.21678.
    >> Share

  31. MITTELDORF C
    Multistaining for a better understanding of lymphoma biology.
    Br J Dermatol. 2022 May 4. doi: 10.1111/bjd.21590.
    >> Share

    March 2022
  32. DOBOS G, Assaf C
    Transcriptomic changes during stage progression of mycosis fungoides: from translational analyses to their potential clinical implications.
    Br J Dermatol. 2022;186:387-388.
    >> Share

  33. XIAO MZX, Hennessey D, Iyer A, O'Keefe S, et al
    Transcriptomic changes during stage progression of mycosis fungoides.
    Br J Dermatol. 2022;186:520-531.
    >> Share

    February 2022
  34. VERMEER MH, Moins-Teisserenc H, Bagot M, Quaglino P, et al
    Flow cytometry for the assessment of blood tumour burden in cutaneous T-cell lymphoma: towards a standardised approach.
    Br J Dermatol. 2022 Feb 14. doi: 10.1111/bjd.21053.
    >> Share

  35. FALKENHAIN-LOPEZ D, Fulgencio-Barbarin J, Puerta-Pena M, Montero-Menarguez J, et al
    Single-centre experience of using pegylated liposomal doxorubicin as maintenance treatment in mycosis fungoides.
    Br J Dermatol. 2022;186:363-365.
    >> Share

    January 2022
  36. KEMPF W, Petrella T, Willemze R, Jansen P, et al
    Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations - Results of an EORTC Cutaneous Lymphoma Group Workshop.
    Br J Dermatol. 2022 Jan 5. doi: 10.1111/bjd.20973.
    >> Share

  37. BLANCHARD G, Guenova E
    Mogamulizumab-associated rash (MAR) mars its efficacy in the treatment of cutaneous lymphoma.
    Br J Dermatol. 2022;186:15-16.
    >> Share

    November 2021
  38. PAPADAVID E, Kapniari E, Pappa V, Nikolaou V, et al
    Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sezary syndrome with variable CD30 positivity.
    Br J Dermatol. 2021;185:1035-1044.
    >> Share

  39. MOYAL L, Arkin C, Gorovitz-Haris B, Querfeld C, et al
    Mycosis fungoides-derived exosomes promote cell motility and are enriched with microRNA-155 and microRNA-1246, and their plasma-cell-free expression may serve as a potential biomarker for disease burden.
    Br J Dermatol. 2021;185:999-1012.
    >> Share

    October 2021
  40. HENDERSON BERG MH, Davison K, Popradi G
    Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: A single-centre retrospective review.
    Br J Dermatol. 2021 Oct 5. doi: 10.1111/bjd.20786.
    >> Share

    September 2021
  41. POSPISCHIL I, Guenova E
    Mycosis fungoides-derived exosomes and their microRNA-1246 cargo: a message from the skin.
    Br J Dermatol. 2021 Sep 14. doi: 10.1111/bjd.20695.
    >> Share

    August 2021
  42. TRUM NA, Zain J, Martinez XU, Parekh V, et al
    Mogamulizumab Efficacy is Underscored by its Associated Rash that Mimics Cutaneous T-cell Lymphoma: A Retrospective Single-Centre Case Series.
    Br J Dermatol. 2021 Aug 24. doi: 10.1111/bjd.20708.
    >> Share

  43. HODAK E
    Is lymph node core-needle biopsy an alternative to excisional biopsy for the accurate staging of mycosis fungoides/Sezary syndrome and predicting the survival of patients?
    Br J Dermatol. 2021;185:251-252.
    >> Share

  44. ORTIZ-ROMERO PL
    The time for new biomarkers in mycosis fungoides/Sezary syndrome is here.
    Br J Dermatol. 2021;185:250-251.
    >> Share

  45. OTTEVANGER R, de Bruin DT, Willemze R, Jansen PM, et al
    Incidence of mycosis fungoides and Sezary syndrome in the Netherlands between 2000 and 2020.
    Br J Dermatol. 2021;185:434-435.
    >> Share

  46. CALVANI J, de Masson A, de Margerie-Mellon C, de Kerviler E, et al
    Image-guided lymph node core-needle biopsy predicts survival in mycosis fungoides and Sezary syndrome.
    Br J Dermatol. 2021;185:419-427.
    >> Share

  47. DOBOS G, De Cevins C, Ly Ka So S, Jean-Louis F, et al
    The value of five blood markers in differentiating mycosis fungoides and Sezary syndrome: a validation cohort.
    Br J Dermatol. 2021;185:405-411.
    >> Share

    July 2021
  48. GAMBICHLER T, Boms S, Hessam S, Tischoff I, et al
    Primary cutaneous anaplastic large cell lymphoma with marked spontaneous regression of organ manifestation after SARS-CoV-2 vaccination.
    Br J Dermatol. 2021 Jul 6. doi: 10.1111/bjd.20630.
    >> Share

    June 2021
  49. SKAYEM C, Beylot-Barry M, de Masson A, Dereure O, et al
    Lymph node and visceral progression without erythroderma or blood worsening in erythrodermic cutaneous T-cell lymphoma: nine cases.
    Br J Dermatol. 2021 Jun 15. doi: 10.1111/bjd.20580.
    >> Share

    May 2021
  50. JONAK C, Alkon N, Rindler K, Rojahn TB, et al
    Single-cell RNAseq profiling in a patient with discordant primary cutaneous B and T cell lymphoma reveals micromilieu-driven immune skewing.
    Br J Dermatol. 2021 May 21. doi: 10.1111/bjd.20512.
    >> Share

  51. ZIMMERMANN C, Boisson M, Ram-Wolff C, Sadoux A, et al
    Diagnostic performance of high throughput sequencing of the T-cell receptor beta gene for the diagnosis of cutaneous T-cell lymphoma.
    Br J Dermatol. 2021 May 3. doi: 10.1111/bjd.20432.
    >> Share

  52. MOLLOY K, Vico C, Ortiz-Romero PL, Scarisbrick JJ, et al
    Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sezary syndrome.
    Br J Dermatol. 2021;184:978-981.
    >> Share

    April 2021
  53. PORCU P, Nikbakht N
    New insights on treatment utilization and outcomes in early-stage mycosis fungoides.
    Br J Dermatol. 2021;184:594-595.
    >> Share

    March 2021
  54. HODAK E, Sherman S, Papadavid E, Bagot M, et al
    Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study.
    Br J Dermatol. 2021;184:524-531.
    >> Share

    August 2020
  55. D'INCAN M, Ingen-Housz-Oro S, Beylot-Barry M, Joly P, et al
    Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas.
    Br J Dermatol. 2020 Aug 18. doi: 10.1111/bjd.19495.
    >> Share

    May 2020
  56. DANGIEN A, Ram-Wolff C, Brice P, Battistella M, et al
    Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas.
    Br J Dermatol. 2020 May 14. doi: 10.1111/bjd.19220.
    >> Share

    February 2020
  57. HWANG S, Johnson A, Fabbro S, Hastings J, et al
    Topical imiquimod monotherapy for indolent primary cutaneous B-cell lymphomas (PCBCL): a single-institution experience.
    Br J Dermatol. 2020 Feb 20. doi: 10.1111/bjd.18961.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016